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Acute and chronic exposure to cannabis and its main psychoactive component, 
9
-
tetrahydrocannabinol (THC), is associated with changes in brain function and cerebral blood flow 
(CBF). We therefore sought to systematically review the literature on the effects of THC on CBF 
following PRISMA guidelines. Studies assessing the acute and chronic effects of THC on CBF, 
perfusion and volume were searched in the PubMed database between January 1972 and June 2019. 
We included thirty-four studies, which altogether investigated 1,259 humans and 28 animals. Acute 
and chronic THC exposure have contrasting and regionally specific effects on CBF. While acute 
THC causes an overall increase in CBF in the anterior cingulate cortex, frontal cortex and insula, in a 
dose-dependent manner, chronic cannabis use results in an overall reduction in CBF, especially in 
the prefrontal cortex, which may be reversed upon prolonged abstinence from the drug. Future 
studies should focus on standardised methodology and longitudinal assessment to strengthen our 































Cannabis is one of the most widely used drugs with over 180 million of the world’s population 
consuming it annually (UNODC, 2016) thus understanding its effects on the brain is paramount. As the 
decriminalisation and legalisation of cannabis spreads, it is important to understand the effects of 
cannabis and its main psychoactive ingredient 
9
-tetrahydrocannabinol (THC). THC is a partial agonist at 
CB1 and CB2 receptors which are mainly expressed in the central nervous system (CNS) and immune 
cells respectively (Ashton, 2001; Pertwee, 2006). Acute intoxication and chronic heavy administration of 
cannabis have been associated with a range of effects, with potential long-term deleterious effects of 
particular concern in adolescence. Chronic heavy use of the drug is associated with increased risk of 
dependence, psychosis and affective disorder (Volkow et al., 2014). Whilst there is some evidence of 
recovery following abstinence, it remains unknown if these effects can be completely reversed upon 
prolonged abstinence from the drug (Pope et al., 2001). Positive subjective acute effects i.e. the ‘high’, 
include euphoria, relaxation and sensory intensification. Adverse acute effects include anxiety, paranoia, 
impaired psychomotor performance and cognitive function (Broyd et al., 2016; Curran et al., 2016). The 
acute psychoactive effects of the drug result from its effects on CB1 receptors (Huestis et al., 2007). 
Cannabinoid receptors are highly and widely distributed in the brain. The areas of the brain with the 
highest receptor expression include the cerebellum, amygdala, frontal lobes and basal ganglia 
(Herkenham et al., 1990; Glass, Faull and Dragunow, 1997). Cannabinoid receptors are also located in 
and around the vasculature. When administered acutely, THC and several endocannabinoids consistently 
induce vasodilation (Ho and Kelly, 2017). Acute cannabis use also results in tachycardia with varied 





As the brain requires ~20% of the body’s oxygen for normal function, regulation of CBF is 
paramount for organism survival. It is widely known that cannabis induces effects on vasculature in 
a region-specific and dose-dependent manner, including for example, the conjunctival vasodilation 
observed during acute cannabis intoxication (Martin-Santos et al., 2010). Yet, effects on cerebral 
vasculature are often overlooked in the literature. THC binds to type 1 endocannabinoid receptors 
(CB1Rs) that are present in arterial tissue (Bilfinger et al., 1998) and regulate the microvascular 
environment via dose-dependent dilation of cerebral arterioles (Ellis, Moore and Willoughby, 1995; 
Filbey et al., 2017). For this reason, it is unclear whether THC-induced effects are due to direct 
effects on vasculature and/or indirect metabolic changes; and the relative contributions of these 
factors to cerebral and cognitive function. A series of processes, including autoregulation, maintain 
resting CBF (Cipolla, 2009). Region-specific changes in neural activity, and subsequent metabolic 
demand, are tightly coupled to changes in regional CBF (Heiss, 1981). This is in part due to the 
relationship between removal of metabolic waste and the supply and use of oxygen and glucose. 
During functional activation therefore, both CBF and neural activity increase (Paulson et al., 2009). 
Changes in regional CBF have been associated with several neuropsychiatric disorders including 
anxiety, psychosis and schizophrenia (Hasler et al., 2007; Kaczkurkin et al., 2017; Kindler et al., 
2017). Given the associations between altered CBF and neuropsychiatric illness, together with a lack 
of a precise mechanistic understanding of how chronic cannabis exposure induces vulnerability to 






Previous reviews (Quickfall and David Crockford, 2006; Chang and Chronicle, 2007; Martin-
Santos et al., 2010; Batalla et al., 2013; Lorenzetti, Solowij and Yücel, 2016) have not focused 





neuroimaging and non-neuroimaging studies in both humans and animals and so it is timely for these 
 










This review was conducted in accordance with the Preferred Reporting Items for Systematic 
Reviews and Meta-analyses (PRISMA) statement. We performed an electronic search using PubMed 
and the following Boolean inputs “(THC OR MARIJUANA OR Cannabis OR tetrahydrocannabinol) 
AND “cerebral blood flow”” and included any items published before 27
th
 June 2019. We then 
screened the abstracts of the reference list of systematic reviews identified in this initial search to 
identify any additional studies that met our inclusion criteria. Our inclusion criteria were as follows: 
 
(1) Studies measuring the effects of acute THC and/or cannabis exposure on cerebral blood flow, 
volume or perfusion in humans and other animals; (2) Studies measuring the effects of repeated THC 
and/or cannabis exposure on cerebral blood flow, volume or perfusion in humans and other animals; 
(3) Studies measuring the effects of repeated THC and/or cannabis exposure on cerebral activation in 
resting state in humans and other animals; (4) Studies measuring the effects of acute THC challenge 
on cerebral activation in resting state in humans and other animals. Our exclusion criteria were as 
follows: (1) single case reports; (2) Studies measuring the effects of chronic or acute THC challenge 
on cerebral activation during a cognitive task in humans and other animals; (3) Studies written in 
language other than English; (4) Studies measuring the effects of maternal THC consumption on 
foetal cerebral blood flow, volume or perfusion in humans and other animals; (5) Studies selecting 










Two-hundred and thirty total papers/records were identified for screening – 169 records 
identified through database searching and 61 additional records identified in reviews. After removing 
duplicates, 134 records remained. We then screened these 134 records and found that after initial 
screening, 90 either did not meet our inclusion criteria or met one of our exclusion criteria. Forty-
four full-text articles were then assessed for eligibility and 10 records were excluded after full-text 
analysis. Therefore, 34 studies were included for data synthesis. These studies were grouped 
according to subject species (human/animal) and effect measured (acute/chronic) producing 4 
subgroups (for more detailed information, see Fig. 1). Three studies measured the effects of acute 
THC challenge or cannabis on cerebral blood flow in animals. Thirteen studies measured the effects 
of acute THC/cannabis challenge on cerebral blood flow in humans. Only 1 study measured the 
effects of repeated THC challenge or cannabis on cerebral blood flow in animals. Finally, 19 studies 
measured the effects of repeated THC challenge or cannabis on cerebral blood flow in humans. In 
total, the effects of THC challenge or cannabis on cerebral blood flow was assessed in 28 animals 
and 1259 humans. 
 
 







13 studies using acute drug challenge in humans matched our inclusion criteria. Of these: 3 
used 
133
Xe inhalation, 2 used Transcranial Doppler flowmetry (TDF), 7 used 
15
O-water positron 
emission tomography (PET) and 1 study used Arterial Spin Labelling (ASL) to measure CBF and 





Mathew et al. (1992a; 1992c) used TDF to demonstrate that inhalation of a ‘joint’ (THC = 
3.55%) with tobacco significantly increased middle cerebral artery (MCA) velocity, and therefore 
global cerebral blood flow, at rest. Both studies also measured heart rate (HR), blood pressure (BP) 
and partial pressure of mean expired CO2 (PECO2,) showing no association between these variables 
and MCA velocity. Despite methodological heterogeneity and small sample sizes, the evidence from 
both studies suggests that acute THC increases cerebral blood flow at rest in those with a previous, 
yet brief, history of exposure to cannabis. 
 
 
In a series of experiments using 
133
Xe inhalation, Mathew et al (1989; 1992b; 1993) 
demonstrated significant changes in global and regional CBF following THC administration in a 
crossover design. A joint-year is used in many studies as a measure of cumulative life exposure to THC. 
One joint-year is equivalent to smoking 365 joints i.e. 1 joint a day, every day for a year. Firstly, the CBF 
of “experienced” (i.e. >4 joint-years) and “inexperienced” (i.e. those that had not smoked cannabis for a 
minimum of 3 years) cannabis users were measured following smoking of a medium-potency (THC = 
2.2%) joint. An hour after smoking the ‘joint’, a significant decrease in global as well as frontal, 
temporal, occipital, central and parietal CBF was observed within “inexperienced” cannabis users, when 
compared to their CBF following a placebo cigarette. However, “experienced users” had no significant 
change in CBF when compared to placebo (Mathew, Wilson and Tant, 1989). Mathew et al. 
(1992a;1993) measured changes in CBF following inhalation of a high-potency (THC=3.55%) and low-
potency (THC = 1.75%) joint in a randomized, double-blind trial of 20 males with previous exposure (at 
least one use) to cannabis and 35 regular cannabis users (minimum of 4 joint years) respectively. In the 
analysis, both studies corrected for HR, respiratory rate (RR), BP, end-tidal CO and forehead skin 
perfusion and demonstrated THC-induced CBF increases particularly in the frontal cortex, right 
hemisphere and anterior regions of the brain, at both THC doses. Mathew et al., (1993) also used TDF to 





related to changes in global CBF in any of the participants. Seven studies used 
15
O-water PET to 
measure CBF in specific areas of the brain. All of the 7 studies, except one, demonstrated an increase 
in global CBF after THC administration (Mathew et al., 1997, 1998, 1999, 2002; O’Leary et al., 
2000, 2007). O’Leary et al. (O’Leary et al., 2002) did not show this significant increase but did show 
increased rCBF in the frontal cortex, insula, cingulate gyrus, temporal poles and cerebellum. This 
change in CBF in temporal poles and cerebellum was also reported in 2 other studies belonging to 
this subgroup (O’Leary et al., 2000; O'Leary et al., 2007). Five of the studies also showed significant 
increased CBF in the frontal cortex, insula and cingulate gyrus (Mathew et al., 1999, 2002, O’Leary 
et al., 2000, 2002, 2007). Another common finding amongst most of the studies was a marked CBF 
increase in anterior regions of the brain. Three of these studies demonstrated THC-induced decreased 
CBF in both the visual and auditory cortices (O’Leary et al., 2000, 2002; O'Leary et al., 2007). Van 
Hell et al. (2011) used ASL to assess the effects of acute THC on both global and region-specific 
perfusion. They demonstrated that acute THC increased perfusion in the anterior cingulate, frontal 
and insula cortex (very similar to evidence found in the PET studies) and decreased perfusion in the 
right post-central gyrus and both occipital gyri. Despite varying doses, methodological heterogeneity 
and in some cases not matching subjects for handedness or sex, the consistency of the results across 
the studies suggests that acute THC challenge causes a region-specific change in CBF – most notably 











Three studies on the effects of acute THC or cannabis challenge on CBF in animals matched 
our inclusion criteria. Ellis, Moore and Willoughby (1995) assessed the effect of THC on cerebral 





vivo, measuring vessel diameter using microscopy. They demonstrated that flushing THC through the 
arteriole caused dose-dependent vasodilation (maximum dilation at 22% THC) with no alteration of 
mean cerebral arterial blood pressure. The effect of an intravenous (IV) THC (100μg/kg) injection on 
cerebral circulation of 4 adult male mongrel dogs was assessed by Beaconsfield et al. (1972), measuring 
CBF directly by the venous outflow technique. They demonstrated that THC led to a 5-12% increase in 
cerebral venous outflow. However, they did not correct for changes observed in heart rate (HR), systolic 
pressure and therefore pulse pressure which would influence venous outflow. Bloom et al. (1997) 
provided a more methodologically rigorous quantification of the effects of THC and its active metabolite, 
11-OH-THC, on CBF. They injected groups of 4-6 rats with one of 6 IV drug treatments: 0.5, 1, 4, 16 
mg/kg THC; 4 mg/kg 11-OH-THC; or vehicle, and used the freely diffusible tracer method (Sakurada et 
al., 1978) to measure regional CBF (rCBF) autoradiographically. Significant THC-induced decreases in 
rCBF were observed in the hippocampus, entorhinal cortex, frontal and medial prefrontal cortex and 
basal ganglia. Significant increases in rCBF were seen mainly in the arcuate nucleus of the 
hypothalamus. However, the THC dose threshold for rCBF decreases ranged from 0.5mg/kg to 16mg/kg, 
the latter of which is an extremely large dose that far exceeds those of human use or experimental studies. 
They did not correct for the significant increase in pCO2 which is a factor known to effect CBF as CO2 
causes vasodilation to increase glucose and oxygen reaching the metabolising tissue (Cipolla, 2009). 
However, as the majority of the areas saw a decrease in rCBF, it is unlikely that correcting for pCO2 
would have altered the results significantly. This is because increased CO2 would increase CBF, however 
as a decrease in rCBF was reported, it would mean that the CO2-mediated increase in CBF was 
overridden by the THC-induced decrease in rCBF. Despite the methodological heterogeneity, small 
sample size and limitations in addressing potential cardiovascular confounds, the evidence from these 3 













Seventeen studies matched our inclusion criteria in this category. Of the 18 studies, 3 used 
133
Xe inhalation, 3 used Doppler ultrasound, 7 used 
15
O-water PET, 1 used single-photon emission 
computed tomography (SPECT), 2 used Magnetic Resonance Imaging (MRI) and 1 study used 
Arterial Spin Labelling (ASL) to measure CBF and perfusion. In 12 of the studies, CBF 
measurements were taken in resting state only. Whereas in the other 7 studies, participants 
performed a variety of tasks which would influence both regional and global CBF measured. Firstly, 
we will focus on the studies that measured CBF at rest only. 
 
 
Three studies used 
133
Xe inhalation to compare CBF in long-term cannabis users after cessation 
versus controls. Tunving et al. (1986) found that global CBF was significantly lower in cannabis users 
compared to controls but found no significant regional flow differences after correcting for partial 
pressure of CO2 in arterial blood (PaCO2). Lundqvist et al. (2001) used the same method to measure CBF 
and demonstrated that chronic cannabis users (0.5-10g hash with 6-8% THC daily for 0.5-21 years) had 
hypofrontality when compared to controls after correcting for PaCO2 and PECO2. However, Mathew et 
al. (1986) found no significant differences between chronic cannabis users (>0.4 joint-years) and age- 
and sex-matched controls. Jacobus et al. (2012) used ASL to compare CBF in chronic cannabis users 
(>0.5 joint-years) and demographically matched controls. After correcting for significant differences in 
alcohol, tobacco and other drug use, compared to controls cannabis users had reduced CBF in the left 
superior and middle temporal gyri, left insula, medial frontal gyri and left supramarginal gyrus. They also 
described increased CBF in the right precuneus in users compared to controls. However, after 4 weeks of 
cessation (confirmed by urinalysis and self-report) there were no significant differences in CBF between 
the two groups. Two studies used 
15





CBF at resting state in chronic cannabis users. Block et al. (2000) provided evidence to suggest that 
chronic cannabis users (>7 times weekly) had lower rCBF in the posterior cerebellum and ventral 
prefrontal cortex and higher rCBF in the right anterior cingulate gyrus when compared to controls. 
Wilson et al. (2000) measured global CBF and found evidence to suggest that males who had a younger 
age of first use had a significantly higher global CBF compared to those who started later. Three studies 
used Doppler ultrasound to analyse resting cerebral blood velocity in chronic cannabis users (Herning et 
al., 2001, 2005; Herning, Better and Cadet, 2008). Each study used different criteria to define chronic 
cannabis use: aligned with DSM criteria for cannabis abuse, 2-350 joints per week, and used cannabis 
>14 times in the past 30 days respectively. All 3 studies provided evidence to suggest that pulsatility 
index, systolic velocity and therefore cerebrovascular resistance in the ACA and MCA are increased in 
chronic cannabis users after cessation compared to controls. This change in cerebrovascular circulation 
did not change after 30 days of abstinence or differ between severe and moderate cannabis users. Two 
studies used MRI to compare resting CBF between chronic cannabis users and healthy comparison 
controls. Sneider et al. (2008) described, using Dynamic susceptibility contrast MRI (DSC-MRI), chronic 
cannabis users (>13 joint-years) to have increased blood volume in the right frontal cortex, temporal 
cortex and cerebellum. However, similar to Herning et al’s (2005) findings, after 28 days, all of the 
regions, except the left temporal and cerebellum which had an increase in blood volume, had no 
significant difference when comparing the two groups. Filbey et al. (2017) used Phase Contrast MRI 
(PC-MRI) to measure CBF in chronic cannabis users (>13 joint-years, daily use in previous 60 days) and 
unmatched controls (significantly greater females in control group). In this way, they provided evidence 
to suggest that cannabis users had higher rCBF in the right pallidum and putamen but overall no 
significant global difference in CBF when compared to controls. Reeves et al. (2007) used 
99m
Tc-
HMPAO SPECT at rest in long-term daily cannabis users (>5 joint-years). However, results differed 
among the 6 cases and there was no control group used which limits the ability to interpret these findings. 





findings are mixed, chronic cannabis users typically have lower global CBF than nonusers. 
Additionally, chronic cannabis use is associated with region-specific effects on CBF, with the most 
consistent decrease occurring in the frontal region. There is some evidence to suggest that these 
effects may be reversible upon prolonged abstinence. However, this is based on a limited number of 
studies and these often used self-report methods. 
 
 
Five studies used 
15
O-water PET to compare chronic cannabis users with occasional/non-using 
controls when performing a task. Vaidya et al. (2011) showed chronic users (>1.7 joint-years) to have a 
greater increase rCBF in the ventral medial prefrontal cortex and cerebellum when performing the Iowa 
Gambling Task (IGT). Bolla et al. (2005) described chronic cannabis users (>1.4 joint-years) to have 
lower rCBF in the orbitofrontal cortex, prefrontal cortex, right cerebellum and right orbital gyrus but 
increased activation in the left cerebellum when performing the IGT. Both studies showed a 
dose/duration-related response, suggesting that increased cannabis use is associated with greater rCBF 
response to achieve the same result. Similarly, Block et al. (2002) and O’Leary et al. (2003) provided 
evidence to suggest that chronic cannabis users (>8 joint-years and unknown joint-years respectively) 
have lower rCBF in the frontal lobe (subdivisions were not investigated further) when performing a 
variety of tests (memory and self-paced counting tasks respectively). Block et al. (2002) also reported 
chronic (>6 joint-years) cannabis users to have a greater increase in rCBF in parts of the cerebellum 
during a memory task. O’Leary et al. (2003) also described chronic cannabis users (average of 10 joint-
years) to have higher increases in rCBF in the left fusiform gyrus, pulvinar nucleus and left caudate 
nucleus and lower rCBF in the cerebellum. Eldreth et al. (2004) compared chronic cannabis users (>1.1 
joint-years) after 25 days of inpatient abstinence to matched controls performing the Stroop task. The 
Stroop task typically increases rCBF in the anterior cingulate cortex and lateral prefrontal cortex. They 





cortex and anterior cingulate cortex, and increased activation in the hippocampus, left occipital lobe 
and paracentral lobule when compared to the control group. 
 
 
Although there is great variability between the results of the chronic cannabis studies, 
preliminary evidence suggests that there may be some reversibility towards the effects that cannabis 
has on CBF. Also, evidence suggests that chronic cannabis users either have to recruit the same 
neural network more strongly when performing the same task or increase activation in compensatory 
circuits to achieve the same result. However, standardized methodology is required to draw any 
region-specific conclusions on the effect of repeated THC on CBF. 
 
 





Only 1 study matched our inclusion criteria in this category. The study by Hayakawa et al. 
(2007) investigated whether tolerance developed to the vasodilatory effect of THC following 
repeated treatment. Two groups of male mice underwent THC treatment schedules followed by 4hr 
MCA occlusion. The first group were given intraperitoneal THC immediately before and 3h after 
MCA occlusion. The second group were given intraperitoneal THC immediately before, 3h after and 
once a day for 14 days after MCA occlusion. Laser-Doppler flowmetry was used to measure CBF 
both during and after the MCA occlusion. In this way, they demonstrated that THC increased CBF in 
the left cortex significantly during the occlusion. However, after 2 weeks of daily THC treatment the 
CBF decreased significantly below the initial recorded value. This suggests that tolerance develops 










To our knowledge, this is the first ever systematic review on the effects of THC on cerebral 
blood flow (CBF). The evidence reviewed suggests that acute THC challenge causes an overall 
increase in CBF – particularly in the anterior cingulate cortex, prefrontal cortex and insula – in a 
dose-dependent manner. However, the evidence assessing the chronic effects of THC suggests that it 
leads to an overall decrease in CBF, particularly in the prefrontal cortex, and that these effects have 
the potential to be reversed upon prolonged abstinence from the drug. These results are important 
because CBF and brain function are highly correlated, suggesting that observations found in BOLD 
fMRI may be skewed by residual THC effects on CBF. The effects observed in both humans and 
animals provide evidence to support three previously reported potential mechanisms of THC on 
CBF: (1) direct vasodilatory effect independent of neuronal activity thus increasing blood flow 
(elucidated by the topical application of THC on rabbit arterioles (Ellis, Moore and Willoughby, 
1995; Wagner et al., 2001; Ho and Kelly, 2017); (2) activation of CB1 receptors leading to region-
specific changes in CBF, including vasodilation and subsequent increase of blood flow (O’Sullivan 
et al., 2005; O’Sullivan, Kendall and Randall, 2005) (3) downregulation of CB1 receptors following 
their prolonged activation leading to the opposite effect seen with initial CB1 receptor activation. 
Although this pattern of acute THC vasodilation is not reported in all studies (Kaymakcalan, Ercan 
and Turker, 1975; Duncan, Kendall and Ralevic, 2004). 
 
 
Taken together, the results of acute THC administration in humans and animals provided consistent 
evidence for an increase in global CBF. Only one acute THC challenge did not measure an overall 
increase in global CBF (Mathew, Wilson and Tant, 1989). Mathew et al. (1989) found an overall 
reduction in CBF – particularly in the frontal lobes. This observation was found in “inexperienced” 





However, in this study, the participants were made to follow a strict smoking pattern which induced 
dysphoria in several participants and was described by several participants as a higher dose than they 
would usually smoke. Also, only the “inexperienced” cannabis users had increased anxiety following 
acute THC challenge whereas the chronic cannabis users did not experience adverse reactions, 
suggesting there is tolerance to the acute anxiogenic effects of the drug (D’Souza et al., 2008). This 
is consistent with D’Souza et al.’s finding of tolerance to acute THC-induced anxiety. This may be 
important as tachycardia, which often occurs with both dysphoria and anxiety, could alter CBF 
(Craske et al., 2017). This research is consistent with the cardiovascular effects of acute THC 
administration which showed THC reduce blood pressure and heart rate and increased blood flow in 
various animal models and in humans (Sultan et al., 2018). 
 
 
Regions with the highest neuronal CB1-receptor density (Herkenham et al., 1990; Glass, Faull 
and Dragunow, 1997) are those with most consistent effects following acute THC challenge (i.e. 
prefrontal cortex, insula and anterior cingulate cortex). These areas are involved in a range of 
functions including planning, decision-making, short-term memory, attention, interoceptive 
awareness, reward processing, emotional processing and impulse control (Bush et al., 2002; 
Critchley et al., 2004; Rossi et al., 2009; Xue et al., 2010; Etkin, Egner and Kalisch, 2011; Stevens, 
Hurley and Taber, 2011; Preston and Eichenbaum, 2013; Beauchaine et al., 2015; Domenech and 
Koechlin, 2015; Curran et al., 2016). Deficits in all of these higher-order functions are associated 
with acute drug intoxication and cannabis use disorder (Campolongo and Fattore, 2015). While there 
is an association between elevated rCBF in the basal ganglia and salience and motivation processes 
linked to the compulsive use of cannabis (Volkow et al., 1996), findings from animal studies indicate 





Most studies assessing the chronic effects of THC on cerebral blood flow found regular users of 
cannabis to have a lower resting global CBF compared to controls. This observation provides 
evidence to support downregulation of globally distributed cannabis receptors following prolonged 
activation. There was great variability between the region-specific effects but the most consistent 
of these was reduced frontal blood flow and neural activity – particularly the ventral and 
dorsolateral prefrontal cortex. However, as most of these studies were cross-sectional it remains 
somewhat unclear whether the differences in CBF of these areas predated or even increased 






In the chronic studies, the abstinence period before data acquisition in studies assessing the 
effects of THC on CBF in chronic cannabis users ranged from a few hours to years. It is important 
that the abstinence period is accurately ascertained and verified to it is clear at what stage of 
“recovery” participants are tested at. Similarly, in the acute challenge studies, the time from 
cessation of THC administration to data collection varied from unknown to several weeks. This adds 
heterogeneity and limits interpretation of acute versus chronic effects. Although there is a debate 
about the existence and time course of these effects, evidence suggests that cognitive function and 
cannabinoid receptor density may recover as quickly as 2-3 days (D’Souza et al., 2016; Scott et al., 
2018). Future studies should use an extended period of abstinence confirmed with biological 
measures in addition to self-report, and continuous measures of CBF post-THC challenge. 
 
 
The potential reversibility of the effects of chronic cannabis exposure on CBF upon prolonged 
abstinence from the drug has important implications (Tunving et al., 1986; Chang and Chronicle, 2007; 
Sneider et al., 2008; Jacobus et al., 2012). It is widely known that CB1 receptors undergo reversible 





al., 2016). This observation would explain why some regions showing increased CBF after acute 
THC challenge in controls have an overall lower resting CBF or show no change/decrease upon 
acute THC challenge in chronic cannabis users. Initially, THC may increase CBF in a region by 
activating CB1 receptors, causing vasodilation. Gradually, after repeated exposure to THC, CB1 
receptors undergo region-specific, reversible, functional down-regulation and receptor density 
decreases so that upon cessation from the drug there is an overall lower CBF (Breivogel et al., 1999; 
Hirvonen et al., 2012). Then, during abstinence CB1 receptor functionality may normalise (Hirvonen 
et al., 2012; D’Souza et al., 2016) resulting in recovery of resting CBF. 
 
 
In several of the studies assessing the chronic effects of THC, the participants performed a 
cognitive task whilst CBF was measured. In the majority of these studies, chronic cannabis users 
showed similar behavioural performance to the controls (or at least achieved a ‘normal’ result) 
despite having a greater amount of non-specific increases in brain activity compared to controls 
(Block et al., 2002; O’Leary et al., 2003; Eldreth et al., 2004; Bolla et al., 2005; Vaidya et al., 2012; 
Amen et al., 2017). This supports a hypothesis proposed by Kanayama (2004) whereby chronic 
cannabis users recruit additional neural resources in order to complete the task at the same level of 
performance as controls. 
 
 
A wide variety of techniques were used to assess CBF. Several of these are less sensitive to regional 
changes (e.g. venous outflow) and are therefore unable to demonstrate the findings seen with modalities 
such as PET and fMRI (Fantini et al., 2016). Additionally, earlier studies focused on the CBF in 
predefined regions of interest as opposed to voxel-based morphometry which is more sensitive to 
changes in regional CBF. Also, several older studies used MCA velocity to infer changes in CBF which 
may not be a valid indicator of changes in CBF. Future studies should also aim to disentangle effects on 





results. The differences in technique used likely contribute to contrasting results observed across 
studies. 
 
In animal studies, THC concentration can be determined using intravenous THC, standardised 
dosing and pharmokinetic parameters. However, in human studies, the concentration of THC is more 
difficult to measure. The cannabis plant also contains over 400 chemical entities that could 
potentially modulate the effect of THC and clinical implications of a change in CBF (Atakan, 2012). 
There was also a high degree of variability in THC dose, both in acute and chronic studies (we have 
included data on THC dose where possible, although, not all studies have reported this). Also, the 
amount of THC consumed depends greatly on the preparation, pattern of use, dose, and route of 
administration. Similarly, there is wide geographical variation in THC content, and evidence that 
THC content in cannabis flowers and other preparations such as hash, resin and cannabis oil has been 
increasing over time (Chandra et al., 2019; Freeman et al., 2019). This may impact whether the 
doses used in the early studies are comparable to more recent studies. Leaving participants to smoke 
at will (i.e. self-titrate) leads to differences in inhaled volumes (Van der Pol et al., 2014). However, 
attempts to standardise smoking timings and volume have led to dysphoria and anxiety which could 
ultimately influence CBF (Mathew, Wilson and Tant, 1989). Future studies should therefore 
investigate the effects of route of administration on THC-induced changes of CBF. However, given 
that the dose-specific effects are not yet fully established, the degree to which this may affect the 
results of these studies is unclear. From the acute challenge studies where dose was available, the 
reported dose ranged from 6mg to 20mg (inhaled) in humans and 100ug/kg to 16mg/kg (IV) in 
animals. These doses are within the range typically consumed by people who use cannabis; 5mg 
THC has been proposed as a ‘Standard THC Unit’ akin to a standard unit of alcohol (Freeman and 
Lorenzetti, in press). It was also not possible to calculate the dose in mg/kg received by the 
participants in the studies where THC was not administered intravenously. In future studies, a 





assess repeatability. Due to the high lipid solubility of THC and cannabis, the bioavailability of THC 
could also be calculated in each participant to overcome this limitation. There also needs to be a 







Furthermore, in the studies assessing both the acute and chronic effects of THC on CBF, it is 
difficult to accurately assess and compare cumulative THC exposure. A range of terms are used to 
describe cannabis users including “regular”, “heavy”, “occasional”, “experienced”, “inexperienced” 
and “chronic” – all with varying definitions. The studies rely on retrospective self-report and 
extrapolation which are not reliable methods. They also fail to capture information on dose per joint, 
which varies according to cannabis potency (Freeman et al., 2014), level of intoxication (Hindocha, 
Freeman and Curran, 2017) and may increase over time as tolerance to the effects of cannabis 
develops (Ashton, 2001). Instead, current measures overemphasise frequency of use which is not 
equal to quantity of use. Many studies use ‘joint-years’ to measure the cumulative exposure to THC. 
This uses a self-reported average of weekly uses multiplied by the time passed since first exposure to 
cannabis, as well as patterns of cannabis consumption changing over time. However, this measure 
may not accurately capture dose due to variability in the strength and amount of cannabis used in 
each joint (Hindocha, Norberg and Tomko, 2018). A way to overcome this limitation would be to 
perform a longitudinal study following cannabis users over time and analysing sample joints at 
regular intervals and confirm abstinence by measuring urinary THC-COOH – the renal metabolite of 
THC. A more cost-effective method is the “roll a joint” paradigm, in which participants are required 
to roll a ‘typical’ joint and this is then analysed and used to estimate to the dose of THC consumed as 
well as tobacco co-administration which is an important confound as tobacco produces changes in 
CBF as well (Domino et al., 2004; Hindocha, Freeman and Curran, 2017). In all of the human 
studies, participants were asked to abstain from any drugs, including nicotine and alcohol, on the day 
of THC administration or CBF measurement. However, it was not considered that long-term use of 
such drugs that alter CBF could influence the findings. In future studies, the long-term poly-
consumption of CBF-altering drugs should be taken into account to understand the degree to which 
they might alter any conclusions. Overall, this review highlights a clear need for standardised 







The sample population varied greatly between studies with differences in socio-economic status, 





abnormalities and handedness. These potential confounding factors were not adequately matched across 
all studies. Several studies used outpatient psychiatric databases or recruited regular users who wanted to 
quit smoking cannabis, complicating the interpretation of those findings. Future studies should match 
these confounding factors and also investigate whether the phase of brain development i.e. age at which 
cannabis exposure occurs effects THC-induced alterations in CBF and the reversibility of effects. Also, 
adolescence is a critical stage of brain development and cannabis is the most commonly consumed illicit 
drug at this age (Malone, Hill and Rubino, 2010). There is evidence that adolescents show a different 
response to adults when administered an acute, weight-adjusted dose of THC (Mokrysz et al., 2016). 
Therefore, it is important to ascertain whether this group is at an increased (or decreased) risk of both 











Chronic and acute cannabis use is associated with region-specific, dose-dependent alterations in 
cerebral blood flow. Acute cannabis use is associated with an overall increase in CBF whereas 
chronic cannabis use is associated with potentially reversible decreases in CBF. Common regions 
implicated include the anterior cingulate cortex, insula and prefrontal cortex in acute cannabis use 
and the frontal cortex in chronic cannabis use. These regions are involved in several higher-order 
functions compromised in acute THC intoxication and cannabis use disorder; and are implicated in 
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Table 1. Acute THC challenge or acute cannabis effects on cerebral blood flow (CBF) in humans  
   Required         
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Mathew et 133Xe 9 12h “Experienced” - 2.2% S Placebo Resting 60m  “Inexperienced” 
al., 1989 inhalation experien  ≥10 joints/week       Global, temporal, 
  ces, 17  for 3 years       occipital, parietal, 
  inexperie         central 
  nced/4  “Inexperienced” -        
    ≥3 years        
    abstinence        
    Controls –        
    unknown previous        
    exposure        
Mathew et Transcrani 10/0 3 months Previous exposure 3.55% S Placebo Resting 0m, 60m MCA velocity  
al., 1992 al Doppler           
 flowmeter           
            
Mathew et 133Xe 20/0 2 weeks Previous exposure 1.75% S Placebo Resting 30m, 60m, Both doses: R  
al., 1992 inhalation    3.55%    120m frontal blood flow  
          High-dose: R  
          temporal blood  
          flow  
          L parietal blood  
          flow  
Mathew et Transcrani 10/0 2 weeks Previous exposure 3.55% S Placebo Resting Continuous MCA CBV – drop  
al., 1992 al Doppler         upon standing  
Mathew et 133Xe 35/0 2 weeks  1.75% S Baseline Resting 30m, 60m, Global CBF  
al., 1993 inhalation    3.55%    120m R frontal blood  
          flow  





Mathew et [15O] H2O 21/11 2 weeks Previous exposure 0.15mg IV Placebo Resting 30m, 60m, 90m, High dose:  
al., 1997 PET    /min    120m Global CBF  
     0.25mg     R/L frontal  
     /min     infusion  
          R/T temporal  
          infusion  
          R/L parietal  
          infusion  
          Cingulate gyrus  
          Insula  
          Basal ganglia  
          Thalamus  
          R amygdala  
          Hippocampus  
          AP ratio  
          Low dose:  
          Global CBFR  
          frontal infusion  
          R cingulate gyrus  
          L insula  
          R/L frontal  
          infusion  
          R/L parietal  
          infusion  
          R/L temporal  
          infusion  
          AP ratio  
Mathew et [15O] H2O 46/0 2 weeks 147 ±165.2 0.15mg IV Baseline Resting Rest, 30m, 60m,   
al., 1998 PET   ‘joints’ per year /min –    120m   
 MRI    20m       
     0.25mg       
     /min –       





Mathew et [15O] H2O 38/21 2 weeks Previous exposure 0.15mg IV Baseline Resting 30m, 60m, 90m, Global CBF Basal ganglia, 
al., 1999 PET    /min    120m L/R ACC blood Hippocampus. 
     0.25mg     flow Amygdala, 
     /min     R frontal blood Thalamus 
          flow  
          R insula blood  
          flow  
Mathew et [15O] H2O 47/0 2 weeks 228.3 ±416.75 0.15mg IV Baseline Resting 30m, 60m, 90m, High-dose: Global  
al., 2002 PET   ‘joints’ per year /min –    120m CBF  
     20m     R hemisphere  
     0.25mg     blood flow  
     /min –     L/R cerebellum  
     20m     Frontal blood  
          flow  
          Insula  
          Low-dose: R  
          cerebellum  
          Both doses:  
          Global CBF  
          AP ratio  
          L/R ACC  
O’Leary et [15O] H2O 5/0 N/A <10 uses/month 20mg S Baseline Auditory 10m R/L Anterior L/L frontal lobe 
al., 2000 PET   for an average of    attention  cingulate L/R Heschl’s 
    3.2 years    task/Dicho  R/L Mesial gyrus 
        tic  frontal lobe L superior 
        listening  L orbital frontal temporal gyrus 
        task  lobe L Hesch’l gyrus 
          Mesial orbital FL R occipital 
          R straight gyrus L precuneus 
          R/L insula Cerebellar vemis 
          R/L temporal pole  





O’Leary et [15O] H2O 12/0 7 days <10 uses/month 20mg S Placebo Auditory 10-15m L ventral R/L superior 
al., 2002 – PET   for an average of    attention  forebrain temporal gyrus 
no gap    6 years    task  R insula L./R motor strip 
between          R temporal pole R caudate 
cigarettes?          L/R anterior L superior parietal 
!          cingulate lobe 
          L/R cerebellum L/R precuneus 
           L/R mesial 
           parietal 
           L/R mesial 
           occipital 
           R occipital 
           (Auditory 
           attention-related 
           temporal lobe, 
           visual cortex, 
           attentional 
           network) 
            
O’Leary et [15O] H2O 12/0 7 days <10 uses (average 20mg S Placebo Auditory 10-15m L/R cerebellum Precuneus 
al., 2007 PET   5.1)/month for an    attention  L/R anterior L occipital 
    average of 3.1    task  cingulate L thalamus 
    years      L/R mesial frontal L parietal 
          lobe L inferior 
          L/R superior temporal 
          temporal gyrus  
          L temporal pole  
          L orbital frontal  
          lobe  
            
Van Hell ASL 26/0 2 weeks ≥4 times/year 6mg S (vaporiser) Placebo Resting 30m (only after L/R anterior R Post-central 
et al., 2011    ≤1/week (1mg    first dose) cingulate gyrus 
     every     L superior frontal L/R occipital 
    Average: 19± 30 min)     cortex gyrus 
    11.2      L/R insula  
    occasions/year       (somatosensory 







Table 2. Acute THC challenge or acute cannabis effects on cerebral blood flow (CBF) in animals   
  
Test 
   
Comparison 
 Greater volume / 
Reduced blood     
Route of 
 
blood flow / 
Author Method Animal / Animal THC dose placebo / Condition volume / flow / 





perfusion       perfusion          
Beaconsfield Venous 4/0 Mongrel 100ug/kg IV Baseline Resting Cerebral venous  
et al., 1972 outflow  dogs     outflow  
Bloom et al., Freely 24/6 Sprague– 0.5, 1, 16 mg/kg IV Placebo Resting Arcuate nucleus CA1 of hippocampus, 
1997 diffusible  Dawley      frontal cortex, medial 
 tracer  derived rats      prefrontal cortex, 
         nucleus accumbens, 
         claustrum, dentate 
         gyrus, entorhinal 
         cortex, globus pallidus 




M Topical Baseline Resting Vasodilation of  







Table 3. Repeated THC challenge and chronic cannabis effects on cerebral blood flow in humans 
 
  Users / Duration of 
Definition of 
Control  Greater 
Reduced volume/blood 
Author Method Controls abstinence from cannabis Condition volume/flow 
“chronic” flow/activation/perfusion   
(Sex) cannabis criteria 
 
velocity /perfusion      
Block et al., [15O] H2O 18/13 26h+ 18±2/week on 0-2 lifetime uses Memory test L/R cerebellum – Prefrontal cortex, BA 
2002 PET   average for the last   posterior cerebellar 1,2,3,21,24,40,41, 42 and 45 
    3.9±0.4   hemisphere, vermis,  
       dentate nucleus  
       , BA 18,19,28,29,30,  
       insula, putamen,  
       tectum  
Block et al., [15O] H2O 17/12 26h >7 times weekly <3 lifetime Resting R anterior cingulate Posterior cerebellum, ventral 
2000 PET    occasions   prefrontal cortex 
Bolla et al., [15O] H2O 11/11 At admission, >4 times/week for at <8 days/month IGT L cerebellum R lateral orbitofrontal cortex 
2005 PET  25d least 2 years   activation, R orbital activation, R dorsolateral prefrontal 
       gyrus cortex activation, L medial 
        orbitofrontal cortex activation, R 
        cerebellum 
Eldreth et [15O] H2O 11/11 25d >3 times/week for at No current or Stroop task L/R hippocampus L DLPFC 
al., 2004 PET   least 2 years past use  R paracentral lobule L perigenual ACC 
       L occipital lobe R anterior ventromedial PFC 
    34.7 (8-63) joints    R anterior DLPFC 
    per week for 7.5 (2-     
    22) years     
Filbey et al., MRI 74/101 72h >5000 lifetime Absence of Resting R pallidum  
2017    occasions AND lifetime daily    
    daily use in past 60 cannabis use    
    days     
Herning et Transcranial 16/19 Within 72h of DSM-IIIR criteria Unknown Resting Pulsatility index and  
al., 2001 Doppler  admission, 28- for cannabis   systolic velocity in  
   30d after dependence/abuse   ACA and MCA – no  
   abstinence    change after  





Herning et Transcranial 54/18 <72h; 28-30d Severe: 78-350 No previous Resting Pulsatility index and  
al., 2005 Doppler  abstinence joints per week exposure –  systolic velocity in  
    Moderate: 17-70 unclear, blank  MCA and ACA –  
    joints per week table  persisted after 1m  
    Light: 2-25 joints     
    per week     
         
Herning et Transcranial 75/33 <72h; 28-30d Used cannabis >14 Unknown Resting Both groups:  
al.,2008 Doppler  abstinence times in past 30   Pulsatility index in  
    days   MCA – no change  
    
Short duration 
  after abstinence  
        
    group: smoked MJ     
    <8 years (56)     
    Long duration     
    group: smoked MJ     
    >8 years (19)     
Jacobus et ASL 23/23 1-17d; 4 weeks >200 lifetime use <4 lifetime use Resting R precuneus – no L superior temporal gyri, L middle 
al., 2012    days days  difference at follow temporal gyri, L insula, medial 
       up frontal gyri, L supramarginal gyrus – 
        no difference at follow up 
Lundqvist et 133Xe 12/14 <5d (2d mean) 0.5-10g (mean 2.4g) Unknown – non Resting  R prefrontal 
al., 2001 inhalation   of 6-8% THC hash smokers   R superior frontal 
    daily for 6m to 21    R/L central 
    years     
Mathew et 133Xe 17/16 12h >5 uses/week for 6 No previous Resting No significant difference between groups 
al., 1986 inhalation   months or more exposure    
O’Leary et [15O] H2O 12   N/A Self-paced Chronic group: Chronic group: ventral forebrain 
al., 2003 PET (chronic),    counting cerebellum increase Frontal lobe activation 
  12     in activation  
  (occasional      Chronic group: Cerebellum 
  )/0     Chronic group: L  
       fusiform gyrus, Ventral forebrain increase, Frontal 
       Pulvinar nucleus of lobe activation, rCBF in cerebellum 
       thalamus, L caudate  
       nucleus  





Reeves et SPECT 6/0 7-10d Daily use >5 years Unknown Resting Each subject had vastly different results 
al., 2007  (compared       
  to 750       
  normals in       
  neurometric       
  database)       
Sneider et DSC-MRI 15/17 6-36h, 7d, 28d >5000 lifetime No cannabis use Resting Cerebral blood  
al., 2008    occasions within the last  volume:  
     month and no  Day 7 – R frontal  
     history of  cortex, R/L temporal  
     cannabis  cortex, cerebellum  
     abuse/dependen  Day 28 – L temporal  
     ce  lobe, cerebellum  
         
Tunving et 133Xe 9/9 1-12 days Cannabis use Absence of Resting  Global CBF – after 60d abstinence no 
al., 1986 inhalation   disorder history of   significant difference when compared 
   4 subjects only:  cannabis use   to controls 
   9d, 14d, 15d,  disorder    
   60d      
         
Valdya et [15O] H2O 46/34 24h >5 times weekly for <7 lifetime IGT task Ventromedial Superior temporal gyrus 
al., 2012 PET   last 2 years occasions, no  prefrontal cortex  
     other  Cerebellar tonsil  
     psychoactive    
     drugs except    
     alcohol    
Wilson et MRI 57/0 2 weeks Unknown (16.8 – N/A Resting Global CBF – if  
al., 2000 [15O] H2O   average age of   cannabis use began  
 PET   onset; mean age   before 17  






Table 4. Repeated THC challenge and chronic cannabis effects on cerebral blood flow in animals 
 
        CBF  
Reduced blood     
THC Route of Comparison 
 
measured X Greater volume/blood 
Author Method Users/Controls Animal Condition volume/ flow dose administration placebo/baseline minutes after flow/activation/perfusion 
        administration  /perfusion 
          
           
Hayakawa Laser Controls used – Male 1mg/kg IP Placebo 4h MCA During 3mg/kg and 10mg/kg: 10mg/kg: Global 
et al., 2007 Doppler number unclear ddY 3mg/kg   occlusion occlusion, day Global CBF – during CBF – after 
 flowmetry  mice 10mg/kg    14 occlusion repeated treatment 
            
